Trials / Conditions / Hepatocellular Carcinoma Resectable

Hepatocellular Carcinoma Resectable

9 registered clinical trials studyying Hepatocellular Carcinoma Resectable — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver C NCT07363356	Eastern Hepatobiliary Surgery Hospital	Phase 2
Not Yet Recruiting	Neoadjuvant Therapy of iIparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma NCT07014150	Peking Union Medical College Hospital	Phase 2
Not Yet Recruiting	Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carc NCT06449846	Zhujiang Hospital	—
Recruiting	Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Base NCT06157060	Zhujiang Hospital	—
Unknown	A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable NCT06003673	First Affiliated Hospital of Fujian Medical University	Phase 4
Unknown	Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial NCT05766605	Zhujiang Hospital	Phase 3
Unknown	A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin NCT04850040	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Phase 2
Completed	Hypermethylation of VTRNA2-1 Promoter in HCC Outcome NCT04177316	Chang Gung Memorial Hospital	—
Completed	Predicting Survival After Surgical Resection for the Entire Spectrum of Anatomically Resectable HCC NCT06294808	National Cancer Centre, Singapore	—